Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population‐based registry study
European Journal of Neurology · 2024-12 · 31 (12)
DOI: 10.1111/ene.16511 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 09.10.2024. Verfasst von Fredrik Piehl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Myasthenia Gravis, Registries, Cost of Illness, Health Care Costs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Background and purpose Health care resource utilization (HCRU) and the economic burden of myasthenia gravis (MG) are significant, but existing studies rarely include comprehensive nationwide data. We examined HCRU and direct and indirect costs associated with MG overall and by disease severity in Denmark, Finland, and Sweden.
Methods
Data were collected retrospectively from nationwide health and social care registries. All individuals ≥18 years of age with ≥2 International Classification of Diseases diagnoses of MG between 2000 and 2020 were included. HCRU, direct (inpatient and outpatient contacts, medication) and indirect costs (early retirement, sick leave, death), and associated factors were calculated.
Results
The full study cohort comprised 8622 people with MG (pwMG). Mean annual numbers of all‐cause secondary health care contacts for pwMG were 3.4 (SD = 8.3), 7.0 (SD = 12.3), and 2.9 (SD = 3.9), with mean annual total costs of €12,185, €9036, and €5997 per person in Denmark, Finland, and Sweden, respectively. Inpatient periods, involving 77%–89% of study participants in the three countries, contributed most to direct costs, whereas the majority of indirect costs resulted from early retirement in Denmark and Finland, and sick leave periods in Sweden. Mean annual total costs were highest with very severe MG (€19,570–€33,495 per person across the three countries). Female sex and comorbidities, such as mental and behavioral disorders and severe infections, were also associated with higher total costs.
Conclusions
This population‐based study shows a high level of HCRU and a significant direct and indirect economic burden of MG across three Nordic countries, especially for severe forms of MG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Neurology, Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- MedEngine Oy, Helsinki, Finland.
- UCB Pharma, Copenhagen, Denmark.
- UCB Pharma, Stockholm, Sweden.
ORCID-Profile: Ingrid Lindberg-Schager, Evangelos Tsitlakidis, Riina-Minna Väänänen
Förderung
- UCB Pharma
Zitieren
APA
Piehl, F., Vissing, J., Mehtälä, J., Berggren, F., Lindberg-Schager, I., Pitsi, D., Tsitlakidis, E., Vesikansa, A., Väänänen, R. M., Ylisaukko-Oja, T., & Atula, S. (2024). Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population‐based registry study. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16511
Vancouver
Piehl F, Vissing J, Mehtälä J, Berggren F, Lindberg-Schager I, Pitsi D, et al. Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population‐based registry study. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16511
BibTeX
@article{Piehl2024,
author = {Piehl, Fredrik and Vissing, John and Mehtälä, Juha and Berggren, Fredrik and Lindberg-Schager, Ingrid and Pitsi, Didier and Tsitlakidis, Evangelos and Vesikansa, Aino and Väänänen, Riina-Minna and Ylisaukko-Oja, Tero and Atula, Sari},
title = {Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population‐based registry study},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {12},
doi = {10.1111/ene.16511}
}
EUVIMED